<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217814</url>
  </required_header>
  <id_info>
    <org_study_id>ACT11575</org_study_id>
    <secondary_id>2010-021020-94</secondary_id>
    <secondary_id>U1111-1115-3763</secondary_id>
    <nct_id>NCT01217814</nct_id>
  </id_info>
  <brief_title>Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis (RA) Who Have Failed Previous TNF-α Antagonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - Demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate [MTX] is superior in
      efficacy to placebo for the relief of signs and symptoms of Rheumatoid Arthritis [RA], in
      patients with active RA who have failed up to 2 Tumor Necrosis Factor α [TNF-α] antagonists.

      Secondary Objectives:

        -  Assess the safety of sarilumab;

        -  Document the pharmacokinetic profile of sarilumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study period for each participant was approximately 22 weeks; including
      up to 4 weeks screening period, 12-week double-blind treatment period and 6-week safety
      follow-up period.

      Participants who completed the 12-week treatment period were offered enrollment in a
      separate long-term extension study (LTS11210/NCT01146652).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was delayed and timelines impacted so that it would not allow completion in a
    reasonable timeframe for informing the future clinical development
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieve 20% improvement from baseline according to the American College of Rheumatology core set disease activity index [ACR20]</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve 50% improvement from baseline according to the American College of Rheumatology core set disease activity index [ACR50]</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve 70% improvement from baseline according to the American College of Rheumatology core set disease activity index [ACR70]</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score [DAS28]</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European League Against Rheumatism [EULAR] response</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with DAS28 remission (DAS28 &lt; 2.6)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of functional and bound sarilumab</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sarilumab 150 mg + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 75 mg/mL, 2 ml once a week for 12 weeks, plus placebo (for golimumab), 0.5 ml every 4 weeks to maintain the blind, in addition to methotrexate [MTX], 15 to 25 mg once a week.
Folic/folinic acid continued according to local standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for sarilumab), 2 ml once a week for 12 weeks, plus placebo (for golimumab), 0.5 ml every 4 weeks to maintain the blind, in addition to methotrexate [MTX], 15 to 25 mg once a week.
Folic/folinic acid continued according to local standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab 50 mg + MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Golimumab 50 mg/0.5 ml, 0.5 ml every 4 weeks for 12 weeks, plus placebo (for sarilumab), 2 ml once a week to maintain the blind, in addition to methotrexate [MTX], 15 to 25 mg once a week.
Folic/folinic acid continued according to local standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab 150 mg + MTX</arm_group_label>
    <other_name>SAR153191</other_name>
    <other_name>REGN88</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab 150 mg + MTX</arm_group_label>
    <arm_group_label>Placebo + MTX</arm_group_label>
    <arm_group_label>Golimumab 50 mg + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Golimumab 50 mg + MTX</arm_group_label>
    <other_name>Simponi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate [MTX]</intervention_name>
    <description>Pharmaceutical form: tablet or solution for injection
Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)</description>
    <arm_group_label>Sarilumab 150 mg + MTX</arm_group_label>
    <arm_group_label>Placebo + MTX</arm_group_label>
    <arm_group_label>Golimumab 50 mg + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic/folinic acid</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Sarilumab 150 mg + MTX</arm_group_label>
    <arm_group_label>Placebo + MTX</arm_group_label>
    <arm_group_label>Golimumab 50 mg + MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of rheumatoid arthritis ≥6 months duration and American College of
             Rheumatology [ACR] Class I-III functional status at screening and baseline visits;

          -  Active disease defined as:

               -  At least 6 of 68 tender joints and 6 of 66 swollen joints at screening and
                  baseline visits, and

               -  hs-C-Reactive Protein [hs-CRP] &gt;10 g/L or Erythrocyte Sedimentation Rate [ESR]
                  &gt;28 mm/hr at screening visit;

          -  Continuous treatment with Methotrexate for at least 12 weeks and on stable dose
             (minimum 10 mg/week) for at least 6 weeks prior to the screening visit;

          -  Patient considered as Primary TNF-α blocker nonresponder. i.e.:

               -  Appropriate for previous TNF-α blocker therapy

               -  Lack of adequate clinical response after at least 3 months TNF-α blocker therapy
                  (up to 2 agents) with Methotrexate or other synthetic disease modifying
                  anti-rheumatic drug [DMARD] co-therapy.

        Exclusion criteria:

          -  Age &lt;18 years or &gt;75 years;

          -  Pregnant or breastfeeding woman or woman of childbearing potential, unwilling to
             utilize adequate contraception or not to become pregnant during the entire study;

          -  Fever (&gt;38°C), or chronic, persistent, or recurring infection(s);

          -  History of demyelinating disease;

          -  Current underlying hepatobiliary disease.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840026</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840043</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840025</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840038</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170004</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170005</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170007</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484008</name>
      <address>
        <city>Durango</city>
        <zip>34270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 9, 2012</lastchanged_date>
  <firstreceived_date>October 7, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>October 31, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
